Literature DB >> 14577649

Transcription factors as molecular targets: molecular mechanisms of decoy ODN and their design.

Naruya Tomita1, Toshio Ogihara, Ryuichi Morishita.   

Abstract

Recent progress in cellular and molecular research has provided a new technique to inhibit target gene expression based on DNA technology such as antisense oligonucleotides (ODN) or decoy ODN. Especially, application of an antisense strategy to regulate the transcription of disease-related genes in vivo has important therapeutic potential to treat or cure a variety of diseases and abnormal physiological conditions. On the other hand, recently, a successful ODN-based approach termed decoy ODN has used synthetic ODN containing an enhancer element that can penetrate cells, to bind to sequence-specific DNA-binding proteins and interfere with transcription in vitro and in vivo. Transfection of cis-element double-stranded decoy ODN has been reported as a new powerful tool in a new class of anti-gene strategies to treat various diseases as gene therapy or as a research tool to examine the molecular mechanisms of expression of a specific gene. Transfection of double-stranded ODN corresponding to the cis-sequence will result in attenuation of the authentic cis-trans interaction, leading to removal of trans-factors from the endogenous cis-elements with subsequent modulation of gene expression. To date, we have chosen several target transcription factors such as NFkappaB (nuclear factor-kappaB) and E2F to prevent the progression of diseases, and negative regulatory element (NRE) for the renin gene and angiotensinogen gene-activating element (AGE) for the angiotensinogen gene to examine the molecular mechanisms of gene expression. In this section, we introduce the principles of the decoy strategy and how to design decoy ODN.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14577649     DOI: 10.2174/1389450033490803

Source DB:  PubMed          Journal:  Curr Drug Targets        ISSN: 1389-4501            Impact factor:   3.465


  14 in total

Review 1.  Inhibiting NF-κB activation by small molecules as a therapeutic strategy.

Authors:  Subash C Gupta; Chitra Sundaram; Simone Reuter; Bharat B Aggarwal
Journal:  Biochim Biophys Acta       Date:  2010-05-21

Review 2.  Discovery and development of the G-rich oligonucleotide AS1411 as a novel treatment for cancer.

Authors:  Paula J Bates; Damian A Laber; Donald M Miller; Shelia D Thomas; John O Trent
Journal:  Exp Mol Pathol       Date:  2009-01-20       Impact factor: 3.362

Review 3.  Targeting STAT3 in cancer: how successful are we?

Authors:  Peibin Yue; James Turkson
Journal:  Expert Opin Investig Drugs       Date:  2009-01       Impact factor: 6.206

4.  Catch and Release DNA Decoys: Capture and Photochemical Dissociation of NF-κB Transcription Factors.

Authors:  Nicholas B Struntz; Daniel A Harki
Journal:  ACS Chem Biol       Date:  2016-04-07       Impact factor: 5.100

Review 5.  Transcription factor decoy oligonucleotide-based therapeutic strategy for renal disease.

Authors:  Naruya Tomita; Naoki Kashihara; Ryuichi Morishita
Journal:  Clin Exp Nephrol       Date:  2007-03-28       Impact factor: 2.801

6.  Treatment of murine Th1- and Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides.

Authors:  Stefan Fichtner-Feigl; Ivan J Fuss; Jan C Preiss; Warren Strober; Atsushi Kitani
Journal:  J Clin Invest       Date:  2005-10-20       Impact factor: 14.808

7.  Optochemical control of deoxyoligonucleotide function via a nucleobase-caging approach.

Authors:  Qingyang Liu; Alexander Deiters
Journal:  Acc Chem Res       Date:  2013-08-28       Impact factor: 22.384

8.  Global functional analyses of cellular responses to pore-forming toxins.

Authors:  Cheng-Yuan Kao; Ferdinand C O Los; Danielle L Huffman; Shinichiro Wachi; Nicole Kloft; Matthias Husmann; Valbona Karabrahimi; Jean-Louis Schwartz; Audrey Bellier; Christine Ha; Youn Sagong; Hui Fan; Partho Ghosh; Mindy Hsieh; Chih-Shen Hsu; Li Chen; Raffi V Aroian
Journal:  PLoS Pathog       Date:  2011-03-03       Impact factor: 6.823

9.  A STAT3-decoy oligonucleotide induces cell death in a human colorectal carcinoma cell line by blocking nuclear transfer of STAT3 and STAT3-bound NF-κB.

Authors:  Inès Souissi; Imen Najjar; Laurent Ah-Koon; Pierre Olivier Schischmanoff; Denis Lesage; Stéphanie Le Coquil; Claudine Roger; Isabelle Dusanter-Fourt; Nadine Varin-Blank; An Cao; Valeri Metelev; Fanny Baran-Marszak; Remi Fagard
Journal:  BMC Cell Biol       Date:  2011-04-12       Impact factor: 4.241

Review 10.  STAT inhibitors for cancer therapy.

Authors:  Muhammad Furqan; Akintunde Akinleye; Nikhil Mukhi; Varun Mittal; Yamei Chen; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-12-05       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.